Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker?

Lupus

Volumn 22, Issue 3, 2013, Pages 229-232

  Chanson, J B ^a,b   De Seze, J ^a,b   Eliaou, J F ^c   Vincent, T ^c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

anti aquaporin 4 antibody; biomarker; follow up; Neuroimmunity; neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; B CELL ACTIVATING FACTOR; GLIAL FIBRILLAR ACIDIC PROTEIN; IMMUNOGLOBULIN G1; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; METHYLPREDNISOLONE; PROTEIN S100B; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; B LYMPHOCYTE; CEREBROSPINAL FLUID; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE;

AQUAPORIN 4; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; NEUROMYELITIS OPTICA;

EID: 84874400573     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312467669     Document Type: Review

References (30)

1. Kallenberg CG, Stegeman CA, Bootsma H, Bijl M, Limburg PC. Quantitation of autoantibodies in systemic autoimmune diseases: Clinically useful?. Lupus. 2006 ; 15: 397-402
2. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003 ; 9: 521-525
3. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 ; 65: 78-83
4. Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord. 2011 ; 4: 111-121
5. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 ; 202: 473-477
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004 ; 364: 2106-2112
7. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009 ; 66: 630-643
8. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009 ; 386: 623-627
9. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010 ; 133: 349-361
10. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
11. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012 ; 78: 665-671
12. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain. 2007 ; 130: 1235-1243
13. Weinstock-Guttman B, Miller C, Yeh E, et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler. 2008 ; 14: 1061-1067
14. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008 ; 131: 3072-3080
15. Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler. 2012 ; 18: 578-586
16. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011 ; 76: 1310-1315
17. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011 ; 18: 997-998
18. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007 ; 69: 2221-2231
19. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009 ; 66: 1164-1167
20. Kalluri SR, Illes Z, Srivastava R, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010 ; 67: 1201-1208
21. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010 ; 7: 52-52
22. Klawiter EC, Alvarez E, Xu J, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 2009 ; 72: 1101-1103
23. Dujmovic I, Mader S, Schanda K, et al. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol. 2011 ; 234: 124-130
24. Moreh E, Gartsman I, Karussis D, Rund D, Hiller N, Meiner Z. Seronegative neuromyelitis optica: Improvement following lymphocytapheresis treatment. Mult Scler. 2008 ; 14: 860-861
25. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 ; 9: 14-14
26. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 ; 72: 53-64
27. Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011 ; 18: 1313-1317
28. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009 ; 80: 575-577
29. Storoni M, Petzold A, Plant GT. The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One. 2011 ; 6: e23489 - e23489
30. Storoni M, Verbeek MM, Illes Z, et al. Serum GFAP levels in optic neuropathies. J Neurol Sci. 2012 ; 317: 117-122